Ziegler, D., & Gries, F
doi:10.1111/cge.12921
, , , ,
The reason comes down to limited safety data, since peptides like semaglutide, tirzepatide, BPC-157, and others have never been tested in pregnant women
however, it negatively affected the fetal weight, yet it was considered negligible due to liraglutides known effect of suppressing appetite (94)
Medical Writing/Editorial Assistance The authors acknowledge Alice Knapton, PhD, Noa Chapman, MSc, and Arianna Psichas, PhD from Costello Medical, UK, for management of the Delphi panel, data analysis, medical writing, and editorial assistance based on the authors input and direction